ATC Group: J01MA Fluoroquinolones

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of J01MA in the ATC hierarchy

Level Code Title
1 J Antiinfectives for systemic use
2 J01 Antibacterials for systemic use
3 J01M Quinolone antibacterials
4 J01MA Fluoroquinolones

Group J01MA contents

Code Title
J01MA01 Ofloxacin
J01MA02 Ciprofloxacin
J01MA03 Pefloxacin
J01MA04 Enoxacin
J01MA05 Temafloxacin
J01MA06 Norfloxacin
J01MA07 Lomefloxacin
J01MA08 Fleroxacin
J01MA09 Sparfloxacin
J01MA10 Rufloxacin
J01MA11 Grepafloxacin
J01MA12 Levofloxacin
J01MA13 Trovafloxacin
J01MA14 Moxifloxacin
J01MA15 Gemifloxacin
J01MA16 Gatifloxacin
J01MA17 Prulifloxacin
J01MA18 Pazufloxacin
J01MA19 Garenoxacin
J01MA21
J01MA22
J01MA23
J01MA24
J01MA25

Active ingredients in J01MA

Active Ingredient Description
Ciprofloxacin

Ciprofloxacin is a fluoroquinolone antibacterial agent. The bactericidal action of ciprofloxacin results from the inhibition of both type II topoisomerase (DNA-gyrase) and topoisomerase IV, required for bacterial DNA replication, transcription, repair and recombination.

Delafloxacin

Delafloxacin inhibits bacterial topoisomerase IV and DNA gyrase (topoisomerase II), enzymes required for bacterial DNA replication, transcription, repair, and recombination.

Gatifloxacin

Gatifloxacin is an 8-methoxyfluoroquinolone with a 3-methylpiperazinyl substituent at C7. The antibacterial action of gatifloxacin results from inhibition of DNA gyrase and topoisomerase IV. The mechanism of action of fluoroquinolones including gatifloxacin is different from that of aminoglycoside, macrolide, and tetracycline antibiotics. Therefore, gatifloxacin may be active against pathogens that are resistant to these antibiotics and these antibiotics may be active against pathogens that are resistant to gatifloxacin.

Lascufloxacin
Levofloxacin

Levofloxacin is a synthetic antibacterial agent of the fluoroquinolone class. As a fluoroquinolone antibacterial agent, levofloxacin acts on the DNA – DNA-gyrase complex and topoisomerase IV.

Lomefloxacin

Lomefloxacin is a synthetic broad-spectrum antimicrobial agent for oral administration. Lomefloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

Moxifloxacin

Moxifloxacin, a fourth-generation fluoroquinolone, has in vitro activity against a wide range of Gram-positive and Gram-negative pathogens. The bactericidal action of moxifloxacin results from the inhibition of both type II topoisomerases (DNA gyrase and topoisomerase IV) required for bacterial DNA replication, transcription and repair.

Nadifloxacin
Norfloxacin

Norfloxacin has a rapid bactericidal action and inhibits synthesis of bacterial deoxyribonucleic acid (DNA). Norfloxacin has a broad spectrum of antibacterial activity against gram-positive and gram-negative aerobic bacteria.

Ofloxacin

Ofloxacin is a quinolone-carboxylic acid derivative with a wide range of antibacterial activity against both Gram-negative and Gram-positive organisms. The primary mode of action of the quinolones is the specific inhibition of bacterial DNA gyrase. This enzyme is required for DNA replication, transcription, repair and recombination.

Pefloxacin

Pefloxacin is a fluoroquinolone antibiotic with broad-spectrum antimicrobial activity. Pefloxacin inhibits the activity of microbial DNA gyrase and topoisomerase IV. This disrupts DNA replication and prevents cell division.

Prulifloxacin

Prulifloxacin is a wide spectrum antibacterial agents belonging to the fluoroquinolone group and provided with high efficacy. Prulifloxacin exerts its antibacterial activity by the selective inhibition of the DNA-gyrase, an essential enzyme present in bacteria and involved in duplication, transcription and repair of DNA.

Sitafloxacin
Tosufloxacin

Related product monographs

Title Information Source Document Type  
AMESOL Film-coated tablet Υπουργείο Υγείας (CY) MPI, EU: SmPC
AVELOX Film-coated tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
AVELOX Solution for infusion Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
CIPLOX Film-coated tablet Health Products Regulatory Authority (IE) MPI, EU: SmPC
CIPRO Film-coated tablet / Oral suspension kit FDA, National Drug Code (US) MPI, US: SPL/PLR
Ciproxin Tablets 250mg Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
ERELAN Film-coated tablet MPI, EU: SmPC
FACTIVE Tablet FDA, National Drug Code (US) MPI, US: SPL/Old
GYRABLOCK Film-coated tablet Υπουργείο Υγείας (CY) MPI, EU: SmPC
LEVAQUIN Film-coated tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
MEDOCIPRIN Film-coated tablet Υπουργείο Υγείας (CY) MPI, EU: SmPC
MEDOFLOXINE Film-coated tablet Υπουργείο Υγείας (CY) MPI, EU: SmPC
OFLOXIN Film-coated tablet Υπουργείο Υγείας (CY) MPI, EU: SmPC
PROFLOXIN Film-coated tablet Health Products Regulatory Authority (IE) MPI, EU: SmPC
QUINSAIR Nebuliser solution European Medicines Agency (EU) MPI, EU: SmPC
QUOFENIX Powder for concentrate for solution for infusion European Medicines Agency (EU) MPI, EU: SmPC
QUOFENIX Tablet European Medicines Agency (EU) MPI, EU: SmPC
TARIVID Solution for infusion Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
TAVANIC Film-coated tablet Health Products Regulatory Authority (IE) MPI, EU: SmPC
VIPROLOX Film-coated tablet Υπουργείο Υγείας (CY) MPI, EU: SmPC